You are here

Applying the Adapsyn genomics platform to the identification, isolation and characterization of immune modulators from the human microbiome

Status: 
Active
Competition: 
Genomic Applications Partnership Program
GAPP Round: 
9
Sector: 
Health
Genome Centre(s):
Ontario Genomics
Project Leader(s):
Michael Surette and Nathan Magarvey (McMaster University)
Receptor Leader(s):
Andrew Haigh (Adapsyn Bioscience Inc.)
Fiscal Year Project Launched: 
2017-2018
Project Description: 

Adapsyn Bioscience has a proprietary platform whereby it applies patented algorithms, proprietary artificial intelligence, and machine learning to genomic and metabolomic data from microbes to identify and characterize novel natural products that can then be developed as novel therapeutics. The company is working with McMaster University and Dr. Michael Surette and his team to systematically mine the human microbiome – the collection of microbes that colonize the body – for compounds that can be used to treat human disease.

The microbiome contains approximately 100 times as many genes as the human genome, and has been shown to produce antibiotics, vitamins, fatty acids, neurotransmitters such as serotonin, histamine and acetylcholine, and immunomodulators. As a result, the microbiome has the potential to affect the nervous system, suppress pathogen growth, and modulate the immune response to invading pathogens. Dysregulation of the microbiome has been implicated in inflammatory bowel disease, cancer, and neurological conditions, and can affect how people respond to immunotherapies.

Dr. Surette and Adapsyn Bioscience are focusing on the microbes responsible for immunological effects of the microbiome. Their work will lead to personalized medicine based on the composition of the microbiome and new treatments for inflammatory diseases and cancer. Adapsyn has secured financing to ensure future development of the results of this project.  The project will also contribute to future partnership opportunities, thus ensuring that the economic benefits of commercialization remain in Canada.